工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors.
A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
合成生物学的快速进展正在推动微生物作为治疗剂的发展。虽然免疫抑制性肿瘤微环境为细菌和治疗有效载荷的系统性递送创造了有利的生态位,但这些物质如果释放到健康组织中可能有害。为解决这一局限性,我们为工程化大肠杆菌Nissle 1917设计了一种时空靶向系统,由叠氮修饰的透明质酸水凝胶和近红外辐射诱导控制。利用温度驱动的遗传状态开关,该系统产生了持久的治疗输出并促进了实体瘤中的治疗活性。叠氮修饰的透明质酸水凝胶与温度敏感的工程化大肠杆菌Nissle 1917的组合提供了对实体瘤的时空靶向,不仅对原发性实体瘤显示出显著的治疗效果,还通过增强TIL(肿瘤浸润淋巴细胞)抑制了癌细胞的转移和复发。该系统具有临床应用潜力。
Rapid advances in synthetic biology are driving the development of microbes as therapeutic agents. While the immunosuppressive tumor microenvironment creates a favorable niche for the systematic delivery of bacteria and therapeutic payloads, these can be harmful if released into healthy tissues. To address this limitation, we designed a spatiotemporal targeting system for engineered Escherichia coli Nissle 1917, controlled by azide-modified hyaluronic acid hydrogel and near-infrared radiation induction.
Using a temperature-driven genetic status switch, the system produced durable therapeutic output and promoted the therapeutic activity in solid tumors.
The combination of azide-modified hyaluronic acid hydrogel and temperature-sensitive, engineered Escherichia coli Nissle 1917 provided spatiotemporal targeting of solid tumors, not only showing significant therapeutic effects on primary solid tumors, but also inhibiting the metastasis and recurrence of cancer cells by enhancing tumor-infiltrating lymphocytes. This system has potential for clinical application.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。